NCT04508439.

Study name	Effect of the use of anticoagulant therapy during hospitalization and discharge in patients with COVID‐19 infection
Starting date	20 June 2020
Contact information	Omar Ramos‐Peñafiel, MD, PhD Hospital Regional de Alta Especialidad de Ixtapaluca Mexico City, Ixtapaluca, Mexico, 56530 +525523351588 | christian.ramos.penafiel@gmail.com
Methods	Double‐blind, 1:1, parallel‐assignment RCT
Participants	130 participants, ≥ 18 years, female and male Inclusion criteria: Patients with a diagnosis of COVID‐19 infection confirmed by RQ‐PCR requiring hospital care for the administration of supplemental oxygen Exclusion criteria: Patients with life expectancy < 48h Patients who require ventilatory support upon admission Age > 75 years or with a history of atrial fibrillation History of venous or arterial thrombosis Severe neurological impairment Absence of a primary caregiver to supervise the administration of medication History of cerebral haemorrhage History of previous use of oral anticoagulants History of major surgery 30 days prior to admission Uncontrolled systemic arterial hypertension KDIGO stage III chronic kidney disease or less Haemodialysis or peritoneal dialysis treatment History of active or inactive cancer Pregnant or postpartum patients
Interventions	Experimental: prophylactic enoxaparin Enoxaparin dose of 1 mg/kg/dose twice daily Comparator: therapeutic enoxaparin Enoxaparin dose of 1 mg/kg/dose daily
Outcomes	Primary LMWH (enoxaparin) and ventilatory support time (time frame: 30 days) Thrombotic complications and rivaroxaban (time frame: 30 days) LMWH (enoxaparin) and length of hospital stay (time frame: 30 days) LMWH (enoxaparin) and mortality rate (time frame: 30 days)
Notes	NCT04508439 | No data provided